Treatment

The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA
Annette van der Helm-van Mil, Robert B M Landewé

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 312-315; DOI: 10.1136/annrheumdis-2019-216716
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study
Emmanuel Monnet, Ernest H Choy, Iain McInnes, Tamta Kobakhidze, Kathy de Graaf, Philippe Jacqmin, Geneviève Lapeyre, Cristina de Min

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 316-323; DOI: 10.1136/annrheumdis-2019-216487
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
Alexis Mathian, Micheline Pha, Julien Haroche, Fleur Cohen-Aubart, Miguel Hié, Marc Pineton de Chambrun, Thi Huong Du Boutin, Makoto Miyara, Guy Gorochov, Hans Yssel, Patrick Cherin, Hervé Devilliers, Zahir Amoura

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 339-346; DOI: 10.1136/annrheumdis-2019-216303
IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study
Frederic A Houssiau, Aikaterini Thanou, Minodora Mazur, Edgar Ramiterre, Danny Alexis Gomez Mora, Maria Misterska-Skora, Risto Alfredo Perich-Campos, Svetlana A Smakotina, Sergio Cerpa Cruz, Bassem Louzir, Thérèse Croughs, Michael Lucas Tee

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 347-355; DOI: 10.1136/annrheumdis-2019-216379
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension
Panagiota Xanthouli, Suzana Jordan, Nicklas Milde, Alberto Marra, Norbert Blank, Benjamin Egenlauf, Matthias Gorenflo, Satenik Harutyunova, Hanns-Martin Lorenz, Christian Nagel, Vivienne Theobald, Mona Lichtblau, Charlotte Berlier, Silvia Ulrich, Ekkehard Grünig, Nicola Benjamin, Oliver Distler

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 370-378; DOI: 10.1136/annrheumdis-2019-216476
Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients
Maria Letizia Urban, Federica Maritati, Alessandra Palmisano, Paride Fenaroli, Francesco Peyronel, Giorgio Trivioli, Stefania Ferretti, Consuelo De Biase, Peter C Grayson, Francesco Pegoraro, Domenico Prisco, Paola Romagnani, Giacomo Emmi, Augusto Vaglio

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 433-434; DOI: 10.1136/annrheumdis-2019-216258
Response to: ‘Catching the falling star: points to consider when using propensity scores’ by Ouyang et al
Sytske Anne Bergstra, Cornelia F Allaart, Robert B M Landewé

Annals of the Rheumatic Diseases Mar 2020, 79 (3) e27; DOI: 10.1136/annrheumdis-2018-214892
Role of linoleic acid in autoimmune disorders: a Mendelian randomisation study
Young Ho Lee

Annals of the Rheumatic Diseases Mar 2020, 79 (3) e28; DOI: 10.1136/annrheumdis-2018-214810
Response to: ‘Role of linoleic acid in autoimmune disorders: aMendelian randomisation study’ by Lee et al
Jie V Zhao, C Mary Schooling

Annals of the Rheumatic Diseases Mar 2020, 79 (3) e29; DOI: 10.1136/annrheumdis-2018-214830
Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero et al
Elien A M Mahler, Michiel JM Minten, Mathilde M Leseman-Hoogenboom, Philip M P Poortmans, Jan Willem Leer, Simone S Boks, Frank H J van den Hoogen, Alfons A den Broeder, Cornelia H van den Ende

Annals of the Rheumatic Diseases Mar 2020, 79 (3) e35; DOI: 10.1136/annrheumdis-2018-214896

Main menu

Treatment

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Treatment

Pages